Wittig-type olefination of alcohols promoted by nickel nanoparticles: Synthesis of polymethoxylated and polyhydroxylated stilbenes

European Journal of Organic Chemistry

Volumn , Issue 34, 2009, Pages 6034-6042

  Alonso, Francisco ^a   Riente, Paola ^a   Yus, Miguel ^a  

^a UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Alcohols; Nanoparticles; Nickel; Olefination; Wittig reactions

Indexed keywords

EID: 70749148015     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200900951     Document Type: Article

References (66)

1. G. Wittig, G. Geissler, Justus Liebigs Ann. Chem, 1953, 580, 44-57.
2. For reviews, see: a) B. E. Maryanoff, A. B. Reitz, Chem. Rev. 1989, 89, 863-927;
3. b) M. Edmonds, A. Abell in Modem Carbonyl Oleflnation (Ed.: T Takeda), Wiley-VCH, Weinheim, 2009, pp. 1-17.
4. R. E. Ireland, D. W Norbeck, J. Org. Chem. 1985, 50, 2198-2200.
5. a) For a review, see: R. J. K. Taylor, M. Reid, J. Foot, S. A. Raw, Acc. Chem. Res. 2005, 38, 851-869;
6. b) For a recent application, see: D. J. Phillips, A. E. Graham, Synlett 2008, 649-652.
7. A. G. M. Barrett, D. Hamprecht, M. Ohkubo, J. Org. Chem. 1997, 62, 9376-9378.
8. S. Shuto, S. Niizuma, A. Matsuda, J. Org. Chem. 1998, 63, 4489-4493.
9. A. Maiti, J. S. Yadav, Synth. Commun. 2001, 31, 1499-1506.
10. R. N. MacCoss, E. P. Balskus, S. V. Ley, Tetrahedron Lett. 2003, 44, 7779-7781.
11. a) A. R. Bressette, L. C. Glover IV, Synlett 2004, 738-740;
12. b) J. Shet, V. Desai, S. Tilve, Synthesis 2004, 1859-1863.
13. F. R. Pinacho Crisostomo, R. Carrillo, T. Martin, F. GarciaTellado, V. S. Martin, J. Org. Chem. 2005, 70, 10099-10101.
14. J. M. Vatéle, Tetrahedron Lett. 2006, 47, 715-718.
15. For reviews, see: a) M. H. S. Hamid, P. A. Slatford, J. M. J.Williams, Adv. Synth. Catal. 2007, 349, 1555-1575;
16. b) T. D. Nixon, M. K. Whittlesey, J. M. J. Williams, Dalton Trans. 2009, 753-762.
17. E. Y. Lee, Y. Kim, J. S. Lee, J. Park, Eur. J. Org. Chem. 2009, 2943-2946.
18. a) J. Gorham, The Chemistry of the Stilbenoids, Chapman & Hall, London, 1995. See, for instance:
19. b) E. Garo, J.-F. Hu, M. Goering, G. Hough, M. O'Neil-Johnson, G. Eldridge, J. Nat. Prod. 2007, 70, 968-973;
20. c) R. Siles, J. F. Ackley, M. B. Hadimani, J. J. Hall, B. E. Mugabe, R. Guddneppanavar, K. A. Monk, J.-C. Chapuis, G. R. Petit, D. J. Chaplin, K. Edvardsen, M. L. Trawick, C. M. Garner, K. G. Pinney, J. Nat. Prod. 2008, 71, 313-320;
21. d) A. Gosslau, S. Pabbaraja, S. Knapp, K. Y. Chen, Eur. J. Pharmacol. 2008, 587, 25-34.
22. For a review, see: K. Ferr-Filmon, L. Delaude, A. Demonceau, A. F. Noels, Coord. Chem. Rev. 2004, 248, 2323-2336.
23. For a monograph, see: B. B. Aggarwall, S. Shishodia (Eds.), Resveratrol in Health and Disease, Taylor & Francis, Boca Raton, FL, USA, 2006.
24. For reviews, see: a) M. C. Pinto, J. A. García-Barrado, P. Mac-as, Recent Res. Devel. Biochem. 2004, 5, 281-290;
25. b) B. Zhou, Z.-L. Liu, Pure Appl. Chem. 2005, 77, 1887-1903.
26. For a review, see: G. L. Russo, Biochem. Pharmacol. 2007, 74, 533-544.
27. For a review, see: A. Minerva, Cosmetic News 2006, 29, 398-404.
28. For a review, see: W.-X. Tian, Curr. Med. Chem. 2006, 13, 967-977.
29. For a review, see: H. I. Rocha-Gonzlez, M. Ambriz-Tututi, V. Granados-Soto, CNS Neurosci. Ther. 2008, 14, 234-247.
30. a) J. J. Heynekamp, W. M. Weber, L. A. Hunsaker, A. M. Gonzales, R. A. Orlando, L. M. Deck, D. L. Vander Jagt, J. Med. Chem. 2006, 49, 7182-7189;
31. b) W. Zhang, M. L. Go, Eur. J. Med. Chem. 2007, 42, 841-850, and references cited therein;
32. c) A. Gosslau, S. Pabbaraja, S. Knapp, K. Y. Chen, Eur. J. Pharmacol. 2008, 587, 25-34.
33. a) S. Sale, R. D. Verschoyle, D. Boocock, D. J. L. Jones, N. Wilsher, K. C. Ruparelia, G. A. Potter, P. B. Farmer, W. P. Steward, A. J. Gescher, Br. J. Cancer 2004, 90, 736-744;
34. b) S. Sale, R. G. Tunstall, K. C. Ruparelia, G. A. Potter, W. P. Steward, A. J. Gescher, Int. J. Cancer 2005, 115, 194-201;
35. c) Z. Ma, O. Molavi, A. Haddadi, R. Lai, R. A. Gossage, Cancer Chemother. Pharmacol. 2008, 63, 27-35.
36. For reviews, see: a) F. Alonso, M. Yus, Chem. Soc. Rev. 2004, 33, 284-293;
37. b) F. Alonso, M. Yus, Pure Appl. Chem. 2008, 80, 1005-1012.
38. a) F. Alonso, J. J. Calvino, I. Osante, M. Yus, Chem. Lett. 2005, 34, 1262-1263;
39. b) F. Alonso, J. J. Calvino, I. Osante, M. Yus, J. Exp. Nanosci. 2006, 1, 419-433.
40. a) F. Alonso, I. Osante, M. Yus, Adv. Synth. Catal. 2006, 348, 305-308;
41. b) F. Alonso, I. Osante, M. Yus, Synlett 2006, 3017-3020;
42. c) F. Alonso, I. Osante, M. Yus, Tetrahedron 2007, 63, 93-102;
43. d) F. Alonso, I. Osante, M. Yus, ARKIVOC 2008, 4, 8-15.
44. a) F. Alonso, P. Riente, M. Yus, Tetrahedron 2008, 64, 1847-1852;
45. b) F. Alonso, P. Riente, M. Yus, Tetrahedron Lett. 2008, 49, 1939-1942.
46. F. Alonso, P. Riente, M. Yus, Synlett 2008, 1289-1292.
47. a) F. Alonso, P. Riente, M. Yus, Synlett 2007, 1877-1880;
48. b) F. Alonso, P. Riente, M. Yus, Eur. J. Org. Chem. 2008, 4908-4914.
49. a) F. Alonso, P. Riente, M. Yus, Synlett 2009, 1579-1582;
50. b) F. Alonso, P. Riente, M. Yus, Tetrahedron Lett. 2009, 50, 3070-3073.
51. This assertion is made on the basis that in every redox process a species is oxidised at the same time that the oxidant agent is reduced. In the present case, we assume that dehydrogenation of the alcohol occurs, leading to the intermediate aldehyde (the "oxidation" product). However, other species resulting from a reduction step are not detected.
52. H. Yamataka, K. Nagareda, K. Ando, T. Hanafusa, J. Org. Chem. 1992, 57, 2865-2869.
53. G. Belluci, C. Chiape, G. Lo Moro, Tetrahedron Lett. 1996, 37, 4225-4228.
54. J. A. Widegren, R. G. Finke, J. Mol. Catal. A 2003, 198, 317-341.
55. M. A. Alli, Y. Tsuda, Chem, Pharm, Bull 1992, 40, 2842-2844.
56. M. B. Andrus, J. Liu, E. L. Meredith, E. Nartey, Tetrahedron Lett. 2003, 44, 4819-4822.
57. a) E. Bernard, P. Britz-Mc-Kibbin, N. Gernigon, J. Chem. Educ. 2007, 84, 1159-1161;
58. b) V. Cardile, R. Chillemi, L. Lombardo, S. Sciuto, C. Spatafora, C. Tringali, Z. Naturforsch., Teil C 2007, 62, 189-195.
59. Y. Asakawa, K. Tanikawa, T. Aratani, Phytochemistry 1976, 15, 1057-1059.
60. M. Murias, N. Handler, T. Erker, K. Pleban, G. Ecker, P. Saiko, T. Szekeres, W. Jaeger, Bioorg. Med. Chem. 2004, 12, 5571-5578.
61. a) M. Murias, W. Jaeger, N. Handler, T. Erker, Z. Horvath, T. Szekeres, H. Nohl, L. Gille, Biochem. Pharmacol. 2005, 69, 903-912;
62. b) Z. Ovesna, K. Kozics, Y. Bader, P. Saiko, N. Handler, T. Erker, T. Szekeres, Oncol. Rep. 2006, 16, 617-624.
63. a) P. Saiko, Z. Horvath, M. Murias, N. Handler, W. Jaeger, T. Erker, M. Fritzer-Szekeres, T. Szekeres, Nucleosides Nucleotides Nucleic Acids 2006, 25, 1013-1017;
64. b) Z. Horvath, M. Murias, P. Saiko, T. Erker, N. Handler, S. Madlener, W. Jaeger, M. Grusch, M. Fritzer-Szekeres, G. Krupitza, T. Szekeres, Exp. Hematol. 2006, 34, 1377-1384.
65. Z. Horvath, S. Marihart-Fazekas, P. Saiko, M. Grusch, M. Oezsuey, M. Harik, N. Handler, T. Erker, W. Jaeger, M. FritzerSzekeres, B. Djavan, T. Szekeres, Anticancer Res. 2007, 27, 3459-3464.
66. P. Saiko, M. Pemberger, Z. Horvath, I. Savinc, M. Grusch, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, T. Szekeres, Oncol. Rep. 2008, 19, 1621-1626.